Axsome Therapeutics, Inc. (AXSM)
NASDAQ
Real-time Data
01:30 PM
Day's Range
205.0952 wk Range
112.90Overview - AXSM - Axsome Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
10.78B
P/E (Trailing)
‪-54.77‬
P/E (Forward)
‪41.27‬
PEG Ratio
‪-16.70‬
Price / Sales (TTM)
‪14.01‬
Price / Book
‪130.42‬
EV / EBITDA
‪-62.38‬
Profitability
Gross Margin
‪92.29%‬
Profit Margin
‪-24.67%‬
Operating Margin
‪-23.41%‬
Return on Assets
‪-16.31%‬
Return on Equity
‪-245.10%‬
Ownership
Shares Outstanding
51.42M
Float
44.46M
Short % of Shares Outstanding
‪10.11%‬
Held by Insiders
‪15.08%‬
Held by Institutions
‪74.57%‬
Price stats
Beta
‪0.72‬
50-Day Avg
‪232.40‬
200-Day Avg
‪191.43‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
21 analysts
Average price target
‪$ 285.42‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AXSM - Axsome Therapeutics, Inc.
Peers - AXSM - Axsome Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- AXSMNASDAQAxsome Therapeutics, Inc.10.88BMarket Cap+43.60%52-week change-56.04P/E (Trailing)‪-24.67%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt62.93BMarket Cap+33.08%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.58BMarket Cap-87.93%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.34BMarket Cap+7.12%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.52BMarket Cap+21.81%52-week change19.30P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.84BMarket Cap+39.72%52-week change-21.44P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.59BMarket Cap+11.71%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - AXSM - Axsome Therapeutics, Inc.
About
Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous system disorders. The company focuses on conditions with limited treatment options, including depression, Alzheimer's…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
